In vitro antitumor activity of silybin nanosuspension in PC-3 cells

Cancer Letters

Volumn 307, Issue 2, 2011, Pages 158-164

  Zheng, Dandan ^a   Wang, Yancai ^a   Zhang, Dianrui ^a   Liu, Zhaoping ^a   Duan, Cunxian ^a   Jia, Lejiao ^a   Wang, Feihu ^a   Liu, Yue ^a   Liu, Guangpu ^a   Hao, Leilei ^a   Zhang, Qiang ^b  

^a SHANDONG UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Antitumor; Cytotoxicity; Nanosuspension; Silybin

Indexed keywords

SILIBININ;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; NANOSUSPENSION; PRIORITY JOURNAL; SUSPENSION;

APOPTOSIS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; MICROSCOPY, FLUORESCENCE; SILYMARIN;

EID: 79957635086     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.028     Document Type: Article

References (18)

1. Velebný S., Hrčkova G., Königová A. Reduction of oxidative stress and liver injury following silymarin and praziquantel treatment in mice with Mesocestoides vogae (Cestoda) infection. Parasitology International 2010, 59:524-531.
2. Hogan F.S., Krishnegowda N.K., Mikhailova M., Kahlenberg M.S. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. Journal of Surgical Research 2007, 143:58-65.
3. Dhanalakshmi S., Agarwal P., Glode L.M., Agarwal R. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. International Journal of Cancer 2003, 106:699-705.
4. Yanyu X., Yunmei S., Zhipeng C., Qineng P. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. International Journal of Pharmaceutics 2006, 307:77-82.
5. Jia L., Zhang D., Li Z., Feng F., Wang Y., Dai W., Duan C., Zhang Q. Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug Delivery 2010, 17:11-18.
6. Elsamaligy M., Afifi N., Mahmoud E. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. International Journal of Pharmaceutics 2006, 308:140-148.
7. Gao L., Zhang D., Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. Journal of Nanoparticle Research 2008, 10:845-862.
8. Wang Y., Zhang D., Liu Z., Liu G., Duan C., Jia L., Feng F., Zhang X., Shi Y., Zhang Q. In vitro andin vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology 2010, 21:155104.
9. Pardeike J., Müller R.H. Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18. International Journal of Pharmaceutics 2010, 391:322-329.
10. Neehar Bhatia J.Z., Woif Douglas M., Agarwal Rajesh Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Letters 1999, 147:77-84.
11. Singh R.P. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocrine Related Cancer 2006, 13:751-778.
12. Singh R.P., Raina K., Deep G., Chan D., Agarwal R. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clinical Cancer Research 2009, 15:613-621.
13. Singh R.P., Raina K., Sharma G., Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clinical Cancer Research 2008, 14:7773-7780.
14. Jung H.J., Park J.W., Lee J.S., Lee S.R., Jang B.C., Suh S.I., Suh M.H., Baek W.K. Silibinin inhibits expression of HIF-1α through suppression of protein translation in prostate cancer cells. Biochemical and Biophysical Research Communications 2009, 390:71-76.
15. Flaig T.W., Gustafson D.L., Su L.J., Zirrolli J.A., Crighton F., Harrison G.S., Pierson A.S., Agarwal R., Glodé L.M. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigational New Drugs 2006, 25:139-146.
16. Desrieux A., Fievez V., Momtaz M., Detrembleur C., Alonsosande M., Vangelder J., Cauvin A., Schneider Y., Preat V. Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium. Journal of Controlled Release 2007, 118:294-302.
17. des Rieux A., Fievez V., Théate I., Mast J., Préat V., Schneider Y.J. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. European Journal of Pharmaceutical Sciences 2007, 30:380-391.
18. Sandri G., Bonferoni M.C., Rossi S., Ferrari F., Gibin S., Zambito Y., Di Colo G., Caramella C. Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. European Journal of Pharmaceutics and Biopharmaceutics 2007, 65:68-77.